BALLOON CATHETER AND METHODS OF TREATMENT USING SAME
20230035425 · 2023-02-02
Inventors
Cpc classification
A61B2017/22074
HUMAN NECESSITIES
A61M2025/1059
HUMAN NECESSITIES
A61M2025/1045
HUMAN NECESSITIES
A61B2017/22051
HUMAN NECESSITIES
A61B17/22012
HUMAN NECESSITIES
A61M2025/109
HUMAN NECESSITIES
A61B18/245
HUMAN NECESSITIES
A61M2025/1052
HUMAN NECESSITIES
A61B2018/00982
HUMAN NECESSITIES
A61B2017/22095
HUMAN NECESSITIES
International classification
Abstract
Balloon catheters with an elongate shaft defining a hollow body have an inflatable balloon at a distal end thereof. The balloon has a plurality of internal chambers that are inflatable to differing pressures. When inflated, the balloon has a generally hourglass shape having a neck between a distal end and a proximal end and a port at the neck that is in open communication the hollow body of the shaft and in open communication with an environment external to the balloon. The balloon catheter is inflated in a lumen of a patient to its hourglass shape with its proximal and distal ends in direct contact with normal endothelium juxtaposed to a target lesion with the neck of the balloon at the target lesion. A cutting tool is deployed through the port and an opening having a flap is cut into the target lesion and the plaque is removed thereof.
Claims
1. A balloon catheter comprising: an elongate shaft having an internal hollow body; and a balloon at the distal end of the shaft, the balloon being inflatable and deflatable in accordance with the pressure of a fluid supplied to the inside of the balloon through the internal hollow body of the shaft; the balloon comprising: a plurality of internal chambers that are inflatable to differing pressures, thereby, when inflated, the balloon has a generally hourglass shape having a neck between a distal end and a proximal end of the balloon; and a port at the neck of the balloon in open communication with a delivery tube housed within the internal hollow body and in open communication with an environment external to the balloon.
2. The balloon catheter of claim 1, wherein the plurality of internal chambers of the balloon are inflated sequentially or simultaneously.
3. The balloon catheter of claim 2, wherein the plurality of internal chambers are controllably inflatable.
4. The balloon catheter of claim 3, wherein the plurality of internal chambers comprise at least a distal chamber, a neck chamber, and a proximal chamber.
5. The balloon catheter of claim 4, wherein the port includes a radially extendable tube fixed to the neck chamber; wherein inflation of the neck chamber extends the tube radially outward.
6. The balloon catheter of claim 1, comprising a radially collapsible conduit juxtaposed to the elongate shaft, radially surrounded by the balloon, and having open distal and proximal ends, when inflated, in fluid communication with the environment.
7. The balloon catheter of claim 1, wherein the elongate shaft is bifurcated at the distal end into a first hollow body and a second hollow body and comprises a flexible saddle between and joining the first and second hollow bodies; wherein at least a most proximal of the plurality of internal chambers is fully circumferential and is positioned on the elongate shaft prior to the flexible saddle, and the port is positioned in one of the first and second hollow bodies.
8. The balloon catheter of claim 7, comprising a radially collapsible conduit juxtaposed to the elongate shaft that is bifurcated to continue along each of the first and second hollow bodied; wherein the radially collapsible conduit has an open proximal end and first and second open distal ends positioned for fluid communication with the environment.
9. The balloon catheter of claim 8, wherein flexible saddle enables the first and second hollow bodies to separate from one another into a Y-shape as the balloon is inflated.
10. The balloon catheter of claim 9, wherein the first balloon portion connected to the first hollow body and the second balloon portion connected to the second hollow body comprise at least two internal chambers each; wherein the first balloon portion and the second balloon portion are less than fully circumferential.
11. The balloon catheter of claim 1, comprising a cuff operatively connecting the balloon to the elongate shaft; wherein the cuff is rotatable relative to the elongate shaft.
12. The balloon catheter of claim 11, wherein the cuff is linearly translatable along the elongate shaft.
13. The balloon catheter of claim 11, wherein the balloon in a deflated state lay inside an outer perimeter defined by the cuff.
14. A method of removing plaque from a lesion in a lumen of a patient in need thereof, the method comprising: deploying a balloon catheter according to claim 1 to a target lesion in need of plaque treatment; inflating the balloon of the balloon catheter to its generally hourglass shape with the proximal and distal ends of the balloon in direct contact with normal endothelium proximal and distal to the target lesion and the neck of the balloon at the target lesion, thereby isolating the target lesion from the remainder of the artery; liquifying the plaque; and removing the plaque from inside the target lesion.
15. The method of claim 14, comprising additional inflation of the balloon to push plaque toward the flap opening.
16. The method of claim 14, comprising determining the lipid burden of the plaque.
17. The method of claim 16, wherein determining the lipid burden includes application of near-infrared spectroscopy plus intravascular ultrasound or a capacitive micromachines ultrasound transducer.
18. The method of claim 14, wherein the method further includes advancing a cutting tool to the target lesion through the port in the balloon catheter; cutting an opening into the endothelium of the target lesion, thereby creating a flap of endothelium and access to plaque inside the target lesion.
19. The method of claim 18, wherein the cutting tool is a laser and the opening is a circular cut and the flap has a connection tether of 25 to 45 degrees.
20. The method of claim 19, wherein the connection tether is at a position of upstream arterial flow, thereby arterial flow holds the flap closed subsequent to the treatment.
21. The method of claim 19, wherein removing the plaque comprises applying a laser set at a preselected frequency to liquefy the lipid burden present, and draining the liquid from the target lesion.
22. The method of claim 21, comprising aspirating inside the target lesion.
23. The method of claim 21, comprising closing the flap.
24. The method of claim 21, comprising administering a drug treatment to one or more of a sub-endothelium space between the endothelium and muscularis, an interior surface of the flap, or an exterior surface of the flap.
25. The method of claim 24, wherein the drug treatment comprises collagen and/or carbon dots comprising stem cells.
26. The method of claim 25, comprising activating collagen by application of an activating wavelength of energy.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
DETAILED DESCRIPTION
[0029] The following detailed description will illustrate the general principles of the invention, examples of which are additionally illustrated in the accompanying drawings. In the drawings, like reference numbers indicate identical or functionally similar elements.
[0030] Turning to
[0031] The hourglass shape of the balloon 120 enables the balloon to be positioned at a stenotic lesion or other treatment site with the treatment site generally centered at the neck 125 thereof with proximal and distal portions of the balloon in contact with healthy tissue surrounding the treatment site. In an artery having a stenotic lesion, in a deployed state as shown in
[0032] The plurality of internal chambers 122 of the balloon 120 are inflatable sequentially or simultaneously and are controllably inflatable. In
[0033] In one embodiment, represented by the dashed lines in
[0034] Still referring to
[0035] Turning now to
[0036] In both embodiments, the balloon 120, 120′ has a length that can vary as needed for each patient, i.e., in correlation to the length of the stenotic lesion and proper placement of the proximal and distal portions of the balloon before and after the plaque. As such, the balloons 120, 120′ can be manufactured in a plurality of different custom lengths. The diameter of the balloon 120, 120′ can vary as needed for each patient, i.e., in correlation to the diameter of the artery or other vessel to receive the balloon catheter 100. In addition to the diameter of the balloon 120, 120′, the diameter of the elongate shaft 102 may vary depending upon the procedure to be carried out and the number and type of tools to be introduced to the treatment site through the port 130 in the balloon catheter 100. Example tools include, but are not limited to light, imaging, cutting, and drug deliver. Likewise, the shape and size of the port 130 can vary as well for the same reasons. In the illustrated embodiments, a single port 130 is shown, but the balloon catheter 100 is not limited thereto. In other embodiments, there can be a plurality of ports radially and/or in the axial direction within the neck of the balloon and elongate shaft and/or in the axial direction. Likewise, the elongate shaft can have one or more ports 131 alignable with any one or more of the plurality of ports 130 of the balloons 120, 120′.
[0037] The balloons 120, 120′ are made of convention, commercially available material, or herein after developed materials. The walls 123 defining the plurality of chambers 122 are waterproof and will not allow fluid to transfer to adjacent chambers. The walls areas strong or elastic as desired to maintain a pre-selected degree of rigidity at deployment. As best represented in
[0038] In both embodiments, the cuff 150 operatively couples the balloon 120, 120′ to the elongate shaft 102 and may have a hollow shaft extending therefrom that carries the balloon and in which the elongate shaft 102 is received. In one embodiment, the cuff 150 is rotatable relative to the shaft 102 and/or is linearly translatable along the shaft 102 (it can be advanced and retracted) to enable an operator to position the balloon 120, 120′ selectively and accurately during deployment at a treatment site and in alignment with a port in the elongate shaft. The rotation of the cuff relative to the elongate shaft can be controlled by an electro-mechanical device or an electromagnetic force or other methods of robotic or machine learning devices operative by a user or a computer. The rotation and translation of the cuff to align the ports 130, 131 can occur before, during, or after deployment. After deployment, the balloon 120, 120′ may be rotated by deflating the balloon partially or fully and then rotating the balloon. The cuff 150 and elongate shaft 102 can include a lock to prevent the balloon 120, 120′ from being rotated while fully inflated.
[0039] The cuff 150 can enclose therein a plurality of valves, one each leading to and in fluid communication with one each of the plurality of chambers 122, 125. This fluid communication can be through independent delivery tubes. Saline or other fluid is delivered to the cuff 150 for distribution to the plurality of chambers 122, 125 for inflation thereof. Each of the plurality of valves can be electronically controlled by the operator or a computer. The cuff 150 may include a distribution chamber in fluid communication with the plurality of valves. The operator or a computer can control the inflation of any segment of the balloon with a desired amount of pressure and to a desired size (within specification limits) by controlling a respective one of the plurality of valves. The components of the cuff and/or the elongate shafts may be made of or include titanium clad material or may be polymer-based material or other suitable material.
[0040] The fluid is delivered to the cuff 150 be either a main deliver tube extending therefrom the length of the transport sheath 200 and elongate shaft 102 to the distribution chamber and or a plurality of individual deliver tubes, one each connected to a respective one of the plurality of valves. Distally, the main delivery tube or the plurality of delivery tubes have some slack therein before attaching to the cuff 150, thereby enabling rotational movement of the cuff relative to the elongate shaft 102. An electromechanical or electro-magnetic or electric or robotic system operates the valves. Sensor feedback from the valves provides operator or robot with information about inflation pressure and volume of fluid in each segment of the balloon. This information from all the valves and segments of balloon of the catheter creates a real time 3-D video display available to the medical professional. The volume and pressure delivered to each of the plurality of chambers 122, 125 of the balloon 120, 120′ are measured at the external controller or distributor system.
[0041] Turning back to
[0042] The balloon 120, 120′ includes a means for measuring the pressure within each of the plurality of chambers 122, 125 of the balloon. The means can be any form of a sensor, such as a pressure sensor, stretch receptor (embedded in a wall of each chamber of the balloon), and/or a pressure transducer. The pressure controller 188 receives signals from the means for measuring the pressure for real time feedback and control of the pressure therein and the fluid flow from the inflation station to the valves in the cuff 150.
[0043] Turning now to
[0044] The pressure controller 188 can have a separate connection relative to the valve controller, but may be included in the terminus 160 of the balloon catheter 100, 100′. This connection may comprise a plurality of male pines and mating female sockets in any arrangement, but preferably having a single orientation for the connection to ensure the correct pin to socket are mated. The male pins and mating female sockets can be protected by an exterior surround sleeve that are mateable to one another as well.
[0045] In all embodiments, the imaging device can be any commercially available imaging device or hereinafter developed technology. In one embodiment, the imaging device is selected from near-infrared spectroscopy plus intravascular ultrasound, fiberoptics, or capacitive micromachine ultrasound transducer. Imaging will be in real time, thereby enabling the operator or computer to make decisions about balloon inflation, balloon size, and balloon positioning relative to a treatment site.
[0046] Turning now to
[0047] In another aspect, with reference to
[0048] The method can include introduction of a tool configured to determine the lipid burden of the target lesion and using such tool to determine whether the lipid burden includes a high lipid burden, a low lipid burden, or a high to low lipid burden ratio. This introduction can include feeding the tool through the elongate shaft 102 to the port 130 and into the external environment, including inside the target lesion after the opening with flap has been cut. The tool can be near-infrared spectroscopy plus intravascular ultrasound or a capacitive micromachine ultrasound transducer, which are also capable of confirming the type of lesion, the lesion's morphology, and anatomical limits. These tools can also be used for imaging the target lesion during all steps of the medical procedure. The capacitive micromachine ultrasound transducer is much smaller than other imaging device, which can provide the benefit of being able to perform the method is smaller lumen, i.e., smaller arteries and veins.
[0049] After the imaging just described, the operator of the balloon catheter can select a point for endothelial entry (where to position the opening and flap). The balloon is positioned accordingly, with ports 130, 131 aligned, and the balloon is inflated such that the proximal and distal chambers of the balloon contact the healthy endothelium proximal and distal to the target lesion, such that the target lesion and surgical field are totally isolated from the remainder of the artery. As discuss above, when the balloon 120, 120′ is inflated, the conduit 140 is also expanded and activated to provide continuous blood flow to the distal segment of the artery to perfuse distal myocardium throughout the method. Since the conduit will restore blood flow to the myocardium that has been “starved” because of the presence of the stenotic lesion, the operator should carefully inflate the balloon at a rate that will not result in a reperfusion arrhythmia.
[0050] Additionally, the method can include administering a drug treatment to one or more of a sub-endothelium space between the endothelium and muscularis, an interior surface of the flap, and an exterior surface of the flap. The drug treatment can include collagen and/or carbon dots comprising stem cells. When collagen is present, the method includes activating the collagen by application of an activating wavelength of energy.
[0051] The stenotic lesion can be evidenced/diagnosed using any prior art techniques or hereinafter developed techniques. The insertion of the transportation sheath 200 can be accomplished using any prior art techniques or hereinafter developed techniques, such as the percutaneous approach.
[0052] With reference to
[0053] When cutting the opening, the laser in cutting the opening, which is typically has a diameter that is equal to the diameter of the aspirator catheter plus 5%, the laser first carves out the desired degrees for the opening and flap and secondly, after switching to deeper laser, heat is applied to loosen the sub-endothelial extracellular matrix and separate the endothelium from extracellular matrix and arterial media. Gentle saline flush is applied, and the laser is used to gently move the endothelial flap away from the plaque. The laser can then be withdrawn in preparation of entering the endothelial space. Gentle aspiration is continuously applied by the aspirator to assure that no sub-endothelial plaque material escapes. Any escaping fluid will be trapped and aspirated by the drain ports 212, see
[0054] Next, still referring to
[0055] Once set and verified by the imaging device 209, the laser is set to an appropriate frequency to liquefy the lipids inside the stenotic lesion. The laser may be retractable, for example, it may be spring loaded 226 for maintaining contact with the plaque. As discussed above, an excimer or exciplex laser is selected depending upon the plaque material, i.e., whether it is high lipid burden or low lipid burden. In one embodiment, the plaque material is or has a high lipid burden and the laser is a 635 nm, 10-mW diode excimer laser. The laser is applied for about 6 minutes to the plaque material. During application of the laser, the laser or the catheter sheath 204 (including the laser) is rotated through a 360 degree turn to ensure all plaque material is being liquified. The transitory pores in the cell membrane of adipocytes open and 99% of fat is released from the adipocytes. All vasculature and extracellular matrix structure should remain unharmed by this laser energy. The aspirator 206 is used as needed to remove debris and the balloon is controllably inflated as needed to ensure that significant portion of adipocytes are exposed to the laser energy and the liquefied fat is being “milked” toward the aspirator 206 and drain ports 212. In other words, the plaque will be liquified or vaporized by the laser and aspirated (sucked) out by the aspirator 206. No material should leak outside into the lumen of the artery due to the diaphragm 222 that seals the opening 210. As the medical procedure continues, the neck chamber of the balloon 120, 120′ can be inflated to have a diameter similar to that of the other plurality of chambers to restore the artery lumen to near its original normal size. However, inflation is stopped to leave a layer of space in the extracellular matrix between the endothelium and the muscularis layer of the artery. The muscularis layer and the artery wall does not receive any excess pressure or damage from laser or aspiration and thus remains intact and unstretched or injured. Using the imaging device, the operator can confirm that all the plaque material has been removed and the lumen of the artery is fully or almost restored to normal size.
[0056] The method includes closing the flap once the plaque has been removed. The method can also include administering a drug treatment to one or more of a sub-endothelium space between the endothelium and muscularis, on an interior surface of the flap, and on an exterior surface of the flap. Of these treatments, only the application to the exterior surface of the flap is performed after the flap is closed. In one embodiment, the drug treatment comprises collagen and/or carbon dots comprising stem cells. When collagen is present, the collagen can be activated by application of an activating wavelength of energy. Any suitable tool can be fed through the elongate shaft to the ports 130, 131 to deliver the drug treatment. In one embodiment, the drug treatment is in the form of a patch. The patch dispenses medications that aid in healing the endothelium at the flap site. In one embodiment, the medication comprises undifferentiated stem cells, such as mesenchymal stem cells. The stem cells differentiate into a single layer endothelial cell and provide a seamless healing of the flap in less than 24 hours.
[0057] Referring back to
[0058] Next, if desired, another patch can be applied to the inside surface of the endothelial flap before the flap is moved to a closed position. The patch can again include a drug treatment of collagen and carbon dot tagged mesenchymal stem cells in pharmaceutically effective amounts. Activation by 210 nm wavelength LED is again appropriate for the same reasons noted above. The flap is moved to the closed position by an appropriate tool. The collagen will keep the flap adhered to sub-endothelial tissue, and the endothelium will reorganize over a period of days, thereby restoring the lumen.
[0059] Once the flap is closed, another patch can be applied to the exterior surface of the flap using an appropriate tool. The patch can again include a drug treatment. Here, the drug treatment can include carbon dots, clopidogrel, and sirolimus in pharmaceutically effective amounts. In one embodiment, the drug treatment includes 1.875 mg of clopidogrel and 140 micrograms of sirolimus. This patch is preferably at least 50% larger than the flap for adequate protection of the normal adjacent endothelium. Hereto, activation by 210 nm wavelength LED is appropriate. The clopidogrel and sirolimus are activated for a time-release by the LED. Clopidogrel will prevent platelet aggregation at the site of endothelial window (similar to a drug eluting stent) and sirolimus will prevent excessive endothelial proliferation in the lumen of the artery.
[0060] Referring again to
[0061] Then, an aspiration catheter is ultrasonically guided 313, 315 into the subendothelial extracellular matrix space and the liquified fatty material is aspirated 317 therefrom. The aspirator catheter may be ultrasonically guided into the subendothelial space before or after the activation of the laser. The benefit of this alternate method is that no window must be cut in the endothelial lining. After removal of the liquified lipid, a drug treatment may be administered 320 the subendothelial space between the endothelium and muscularis in one or more locations in or near the target lesion. The drug treatment can include collagen and/or carbon dots comprising stem cells. When collagen is administered, the method includes activating the collagen and/or carbon dots by application of activating wavelength energy. In one embodiment, the drug treatment is a collagen-carbon dot complex.
[0062] After either of the methods discussed above are completed, administration of a drug treatment(s) to the target lesion site 320 occurs and thereafter the tools, balloon catheter, and transportation sheath are removed from the patient. Following the medical procedure, the medical professional may instruct the patient to take baby aspirin (81 mg), one per day, thereafter for a pre-selected time period or for the life of the patient. Plavix oral therapy daily may be prescribed as well for a selected time period, such as 3 months when a stent is not deployed or one year when a stent is deployed.
[0063] Multiple advantages result from use of the balloon catheter and methods of treatment therewith. The primary goals being recanalization of a stenotic vessel, preventing endothelial and arterial damage, and reducing the plaque burden without spreading it into adjacent normal artery wall. Controlled inflation of the balloon catheter into its plurality of chambers reduces the risk of damage to the blood vessel or its internal structure, aneurysm, dissection, and collapse of an artery. The controlled inflation also provides control over inflation at a bend in a vessel or an occlusion at a fork or branch origin of a segmental artery. The balloon catheter disclosed herein, in contrast to conventional balloon catheter technology, reduces deformation and degree of tensile strength applied on the overall artery by inflation at lower amounts of cumulative pressure against the arterial internal lining (intima).
[0064] The medical procedure disclosed herein should eliminate the use of a stent in most instances, and when a stent needs to be deployed, both minimum stent material and minimum pressure will be needed in the deployment. When stenting is unavoidable, a protective layer for the endothelium will be created and placed through nanotechnology. This will both limit endothelial damage and prevent damage to the original endothelium. Commercially available biodegradable stents, which gradually degrade and gets absorbed in the body or eliminated by excretion of the biodegradable materials, may also be deployed after the medical procedure disclosed herein.
[0065] The balloon catheters disclosed herein and the various methods of use of such balloon catheters can be implements to treat various conditions of the coronary artery, such as but not limited to: atheromatous sub-total occlusion; critical stenosis; and atheromatous plaque stenosis; atheromatous sub-total occlusion; critical stenosis of the carotid artery; critical (sub-total) or non-critical renal artery stenosis; femoral and popliteal artery atheromatous stenosis; ileo-femoral atheromatous stenosis; aorto-Iliac atheromatous stenosis; atheromatous pulmonary artery stenosis; and intra-cerebral atheromatous sub-critical stenosis. When the balloon is bifurcated, treatments can include bifurcation coronary artery stenosis in left main coronary artery, left anterior descending artery, or left circumflex artery, or bifurcation coronary artery stenosis in the bifurcation aorto-iliac stenotic lesions, bifurcation ileo-femoral stenotic lesions, and bifurcation femoral-popliteal lesions.
[0066] Although the invention is shown and described with respect to certain embodiments, modifications will occur to those skilled in the art upon reading and understanding the specification, and the present invention includes all such modifications.